Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold

Journal of Medicinal Chemistry

Volumn 42, Issue 26, 1999, Pages 5426-5436

  Cheng, Menyan ^a   De, Biswanath ^a   Almstead, Neil G ^a   Pikul, Stanislaw ^a   Dowty, Martin E ^a   Dietsch, Charles R ^a   Dunaway, C Michelle ^a   Gu, Fei ^a   Hsieh, Lily C ^a   Janusz, Michael J ^a   Taiwo, Yetunde O ^a   Natchus, Michael G ^a   Hudlicky, Tomas ^b   Mandel, Martin ^b,c  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b University of Florida ^*  (United States)

^c Orgachem   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CGS 27023A; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; PROLINE DERIVATIVE; PYRROLIDINE DERIVATIVE; STROMELYSIN; TANOMASTAT;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

ANIMALS; ILEUM; INTESTINAL ABSORPTION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; PROLINE; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033619976     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9904699     Document Type: Article

References (43)

1. (a) Lafleur, M.; Underwood, J. L.; Rappolee, D. A.; Werb, Z. Basement Membrane and Repair of Injury to Periferal Nerve; Defining a Potential Role for Macrophages, Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases-1. J. Exp. Med. 1996,184, 2311-2326.
2. (b) Buisson, A. C.; Gilles, C.; Polette, M.; Zahm, J. M.; Birembout, P.; Tournier, J. M. Wound Repair-Induced Expression of Stromelysins is Associated with the Acquisition of a Mesenchymal Phenotype in Human Respiratory Epithilial Cells. Lab. Invest. 1996, 74, 658-669.
3. (c) Woessner, J. F., Jr. Metalloproteinases and Their Inhibitors in Connective Tissue Remodeling. FASEB J. 1991, 5, 2145-2154.
4. Folkman, J.; Shing, Y. Angiogenesis J. Biol. Chem. 1992, 267, 10931-10934.
5. Cawston, T. Metalloproteinase Inhibitors and the Prevention of Connective Tissue Breakdown. Pharmacol. Ther. 1996, 70, 163-182.
6. (a) Ahrens, D.; Koch, A. E.; Pope, R. M.; Steinpicarella, M.; Niedbala, M. J. Expression of Matrix Metalloproteinase 9 (96-kd Gelatinase B) in Human Rheumatoid Arthritis. Arthritis Rheum. 1996, 39, 1576-1587.
7. (b) Blaser, J,; Triebel, S.; Maajosthusmann, U.; Romisch, J.; Krahlmateblowski, U.; Freudenberg, W.; Fricke, R.; Tschesche, H. Determination of Metalloproteinases, Plasminogen-Activators and their Inhibitors in the Synovial Fluids of Patients with Rheumatiod Arthritis During Chemical Synoviorthesis. Clin. Chim. Acta 1996, 244, 17-33.
8. Overall, C. M.; Wiebkin, O. W.; Thonard, J. C. Demonstration of tissue Collagenase Activity in vivo an its Relationship to Inflammation Severity in Human Gingiva. J. Periodontal Res. 1987, 22, 81-88.
9. (a) Yong, V. W. The potential Use of MMP Inhibitors to Treat CNS Diseases. Expert Opin. Invest. Drugs 1999,94, 2177-2182.
10. (b) Maeda, A.; Sobel, R. A. Matrix Metalloproteinases in the Normal Human Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions. J. Neuropathol. Exp. Neurol. 1996, 55, 300-309.
11. (c) Chandler, S.; Coates, R.; Gearing, A.; Lury, J.; Wells, G.; Bone, E.; Matrix Metalloproteinases Degrade Myelin Basic Protein. Neurosci. Lett. 1995, 201, 223-226.
12. (d) Hewson, A. K.; Smith, T.; Leonard, J. P.; Cuzner, M. L. Suppression of Experimental Allergic Encephalomyelitis in the Lewis Rat by the Matrix Metalloproteinase Inhibitor Ro31-9790. Inflamm. Res. 1995, 44, 345-349.
13. (a) Brown, P. D. Matrix Metalloproteinases in Gastrointestinal Cancer. Gut 1998, 43, 161-163.
14. (b) Chambers, A. F., Matrisan, L. M. Changing Views of the Role of Matrix Metalloproteinases in Metastasis. J. Natl. Cancer Inst. 1997, 89, 1260-1270.
15. (c) Yu, A. E.; Hewitt; R. E.; Connor, E. W.; Stetler-Stevenson, W. G. Matrix Metalloproteinases: Novel Targets for Directed Cancer Therapy. Drugs Aging 1997, 11, 229-244.
16. (d) Zuker, S.; Lystik, R. M.; Zarrabi, H. M.; Moll, U.; Tickle, S. P.; Stetler-Stevenson, W.; Baker, T. S.; Docherty, A. J. P. Plasma Assay of Matrix Metalloproteinases (MMP's) and MMP-Inhibitor Complexes in Cancer. Ann. N.Y. Acad. Sci. 1994, 732, 248-262.
17. (a) Beckett, R. P.; Whittaker, M. Matrix Metalloproteinase Inhibitors 1998. Expert Opin. Ther. Patents 1998, 8, 259-282.
18. (b) White, A. D. Bocan, T. M. A.; Boxer, P. A.; Peterson, J. T.; Schrier, D. Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase Inhibitors. Curr. Pharm. Des. 1997, 3, 45-58.
19. (c) Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Inhibition of Matrix Metalloproteinases: Structure Based Design. Curr. Pharm. Des. 1996, 2, 624-661.
20. (a) Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C.-B.; Arner, E. C.; Copeland, R. A.; Covington, M. B.; Hardman, K. D.; Wasserman, Z. R.; Jaffee, B. D.; Decicco, C. P. Macrocyclic Hydroxamate Inhibitors of Matrix Metalloproteinases and TNF-α Production. Biorg. Med. Chem. Lett. 1999, 9, 1279-1284.
21. (b) Natchus, M. G.; Cheng, M.; Wahl, C. T.; Pikul, S.; Almstead, N. G.; Bradley, R. S.; Taiwo, Y. O.; Mieling, G. E.; Dunaway, C. M.; Snider, C. E.; McIver, J. M.; Barnett, B. L.; McPhail, S. J.; Anastasio, M. B.; De, B. Design and Synthesis of Conformationally-Constrained MMP Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2077.
22. (a) MacPherson, L. J.; Parker, D. T. New Aryl-sulfonyl-amino-hydroxamic Acid Derivatived - Useful as Metalloprotease Inhibitors for Treating Arthritis, Ulcers, Periodontal Disease, Tumor Metastasis, HIV Infections, etc. European Patent Application. EP606046A, 1993.
23. (b) MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V. S.; Parker, D. T. Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits. J. Med. Chem. 1997, 40, 2525-2532.
24. (a) Pikul, S.; McDow-Dunaway, K. L.; Almstead, N. G.; De, B.; Natchus, M. G.; McPhail, M. V.; Snider, C. E.; Taiwo, Y. O.; Rydel, T.; Dunaway, C. M.; Gu, F.; Mieling, G. E. Discovery of Potent, Achiral Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1998, 41, 3568.
25. (b) Almstead, N. A.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis and Biological Evaluation of Potent Thiazine and Thiazapine Based MMP Inhibitors. 1999, in press.
26. (a) Fieser, L. F.; Fieser, M. Reagents for Organic Synthesis; John Wiley and Sons, Inc.: New York, 1967; Vol. 1, p 478.
27. (b) Hauser, C. R.; Renfrow, W. B., Jr. Org. Synth. Coll. Vol. 1943, 2, 67.
28. (a) Hudlicky, T.; Zingde, G. S.; Natchus, M. G.; Ranu, B. C.; Papadopoulos, P. J. System Oriented Design of Triquinanes: Stereocontrolled Synthesis of Pentallenic Acid and Pentalenene. Tetrahedron 1987, 43, 5685.
29. (b) Conia, J. M., Limasset, J. C. J. Bull. Soc. Chim. Fr. 1967, 6, 1936.
30. In the course of our olefination experimentation we observed a curious electrophilic preference of the dithiane anion below for an ester moiety over a ketone moiety. The structure of the product was confirmed by X-ray crystallography. For reference, see: (a) Muzard, M.; Portella, C. Synthesis 1992, 965.
31. (b) Carey, F. A.; Court, A. S. J. Org. Chem. 1972, 37, 1926. (equation presented)
32. Knight, C. G., Willenbrock, F., Murphy, G. A. A Novel Coumarin-labeled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases. FEBS Lett. 1992, 296, 263-266.
33. Okada, Y.; Nagase, H.; Harris, E. D. A Metalloproteinase from Human Rheumatiod Synovial Fibroblasts that Digests Connective Tissue Matrix Components. Purification and Characterization. J. Biol. Chem. 1986, 261, 14245-14255.
34. There is general knowledge that sulfonyl substituents go into the P1′ pocket which is much more shallow for MMP-1 and -7 than the other enzymes of the family. Bode, W.; Fernandez-Catalan, C.; Grams, F.; Gomis-Ruth, F.-Z.; Nagase, H.; Tscheche, H.; Maskos, K. Insights into MMP-TIMP Interactions. Ann. N.Y. Acad. Sci. 1999, 878, 73-91.
35. Protein Data Bank file name: 1D7X.
36. (a) See ref 12.
37. (b) Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
38. (c) Gonella, N. C.; Li, Y.-C.; Zhang, X.; Paris, C. G. Bioactive Conformation of a Potent Stromelysin Inhibitor Determined by X-nucleus Filtered and Multidimensional NMR Spectroscopy. Bioorg. Med. Chem. 1997, 5, 2193-2201.
39. It has been demonstrated in the literature that the R-oriented oxygen plays a more significant role in binding than does the S-oriented oxygen, and this is believed to be due to its closer relative distance to the enzyme: Pikul, S.; McDow-Dunham, K.; Almstead, N. G.; De, B.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; Mieling, G. E. Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases. J. Med. Chem. 1999, 42, 87-94.
40. Dowty, M. E.; Dietsch, C. R. Improved Prediction of In-Vivo Peroral Absorption from In-Vitro Intestinal Permeability Using an Internal Standard to Control for Intra- and Inter-Rat Variability. Pharm. Res. 1997, 14, 1792-1797
41. Desai, S. R.; Liu, D. Z.; Thakker, D. R. The Unusual Effect of Pyridyl Group on the Transcellular Transport of Compounds Across the Caco-2 Cell Monolayers. Pharm. Res. 1997, 14, S-21.
42. Cremlyn, R. J.; Cronje, T.; Goulding, K. Some Phenoxybenzenesulfonyl Chlorides and Related Compounds. Aust. J. Chem. 1979, 32, 445-452.
43. Schraufstatter, E.; Schmidt-Kastner, G.; Wirth, W. Ger. Patent 1,078,129.